Tirzepatide (LY3298176): Inside the GIP-Based Dual Agonist, From Molecule to FDA Record

Most coverage of tirzepatide starts and ends with its clinical trials. This Vial Post explainer takes a different route and looks at the molecule itself: what is written into its 39-residue chain, why pharmacologists describe it as an "imbalanced" and "biased" agonist, what cryo-electron microscopy has revealed about how it sits inside its two target receptors, and how its regulatory record unfolded between 2021 and 2025.

Nothing below is guidance on use in people or animals. The approved tirzepatide medicines are prescription products made by their sponsor; laboratory material sold under the same name is a separate thing, a point covered in the regulatory section.

At a Glance

• Identity: a 39-amino-acid modified peptide built on the sequence of glucose-dependent insulinotropic polypeptide (GIP), carrying a C20 fatty diacid. The FDA label gives a molecular weight of 4813.53 Da and the empirical formula C225H348N48O68 (FDA Mounjaro label 2022).
• Targets: the GIP receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), the receptors for the two native incretin hormones (FDA Mounjaro label 2022).
• Pharmacology in one line: stronger engagement of GIPR than GLP-1R, and at GLP-1R a preference for cyclic AMP signaling over beta-arrestin recruitment (Willard 2020).
• Regulatory record: FDA approval as Mounjaro on May 13, 2022 under NDA 215866, and as Zepbound on November 8, 2023 (FDA Mounjaro approval letter 2022; FDA Zepbound announcement 2023).

Reading the Molecule Line by Line

The prescribing information spells out the structure. Tirzepatide is based on the GIP sequence, includes two non-coded amino acids (aminoisobutyric acid, abbreviated Aib) at positions 2 and 13, ends in a C-terminal amide, and has a lysine at position 20 that is attached through a linker to 1,20-eicosanedioic acid, a 20-carbon fatty diacid (FDA Mounjaro label 2022).

Several of those design choices can be traced to specific statements in the record:

• The fatty diacid. The label's mechanism section says this C20 moiety enables binding to albumin and prolongs the half-life. Elsewhere the label reports that tirzepatide is about 99% bound to plasma albumin and has an elimination half-life of roughly 5 days (FDA Mounjaro label 2022).
• The GIP backbone. Structural work found that tirzepatide closely resembles native GIP in the way it activates GIPR (Sun 2022), which fits a peptide whose sequence starts from GIP rather than from GLP-1.
• Sequence and lipid together. The same study concluded that the fatty acid modification, combined with the amino acid sequence, determines how this multi-receptor agonist works (Sun 2022). In other words, the lipid is not just a half-life extender; it is part of the pharmacology.

"Imbalanced" and "Biased": What Those Labels Mean

The two adjectives come from a 2020 JCI Insight paper. Willard and colleagues developed a way to estimate how much of each receptor tirzepatide occupies at clinically relevant exposure, and found greater engagement of GIPR than GLP-1R. That is the "imbalanced" part (Willard 2020).

The "biased" part concerns what happens after binding. At GIPR, tirzepatide mimicked native GIP. At GLP-1R it behaved differently from GLP-1 itself: it favoured cyclic AMP generation over beta-arrestin recruitment and was weaker at driving receptor internalization. In primary islets, beta-arrestin 1 limited the insulin response to GLP-1 but not to GIP or tirzepatide (Willard 2020).

For anyone designing receptor assays, the practical lesson is that a single readout can mislead. A cyclic AMP assay on its own would capture tirzepatide's activity at GLP-1R but miss the reduced arrestin recruitment and internalization that distinguish it from the native hormone. Pairing a second-messenger readout with an arrestin or internalization readout is what exposed the difference in the original work.

What the Cryo-EM Structures Add

Two independent groups published structures in 2022.

• Zhao and colleagues (Nature Communications) solved cryo-EM structures of tirzepatide bound to GIPR and to GLP-1R, alongside structures of peptide 20, an experimental triple agonist, bound to GIPR, GLP-1R and the glucagon receptor. The authors describe shared and distinct features that underlie dual and triple agonism at near-atomic resolution (Zhao 2022).
• Sun and colleagues (PNAS) combined cryo-EM with molecular dynamics simulations. They report that tirzepatide differs markedly from GLP-1 in how it activates GLP-1R, producing less agonist-induced receptor desensitization, while resembling GIP at GIPR (Sun 2022).

A note on authorship: most authors of the discovery paper, the 2020 pharmacology paper and the PNAS structure paper list Eli Lilly affiliations (Coskun 2018; Willard 2020; Sun 2022), and the conflict-of-interest statements of the 2020 and 2022 papers disclose that employment (Willard 2020; Sun 2022). The Zhao structures came from academic institutions in China whose authors declared no competing interests (Zhao 2022). Having one industry and one academic structural study pointing in a compatible direction is useful corroboration.

A Timeline From Discovery Paper to Shortage List

2018: Lilly scientists describe LY3298176 as a fatty-acid-modified peptide with dual GIP and GLP-1 receptor activity. It was characterized in cell lines expressing recombinant or endogenous incretin receptors and in mice, then taken into a phase 1 study whose primary objective was safety and tolerability; 142 people received at least one dose of LY3298176, the comparator dulaglutide, or placebo (Coskun 2018).

2020: The imbalanced and biased pharmacology is reported (Willard 2020).

September 2021: Lilly's new drug application for Mounjaro is dated September 14 and received by the FDA on September 15, 2021 (FDA Mounjaro approval letter 2022).

May 13, 2022: The FDA approves NDA 215866 for Mounjaro (FDA Mounjaro approval letter 2022).

2022 onward: Tirzepatide injection enters the FDA drug shortage list; the agency later wrote that it had been in shortage since 2022 because of increased demand (FDA compounding statement 2024).

November 8, 2023: The FDA approves Zepbound, whose active ingredient is the same tirzepatide already sold as Mounjaro. The agency notes that the application received Priority Review and Fast Track designations (FDA Zepbound announcement 2023).

October 2, 2024: The FDA determines that the tirzepatide injection shortage has been resolved. On October 22, as part of litigation, that decision is remanded to the agency for reevaluation (FDA compounding statement 2024).

December 19, 2024: After reevaluating, the FDA again finds the shortage resolved and sets transition periods during which it did not intend to act against compounders over shortage-dependent violations: until February 18, 2025 for state-licensed 503A pharmacies and until March 19, 2025 for 503B outsourcing facilities (FDA compounding statement 2024).

What the Label Records About Nonclinical Findings

The Mounjaro label carries a boxed warning based on rodent data: in male and female rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and the label states that human relevance has not been determined (FDA Mounjaro label 2022). That finding is part of the compound's documented nonclinical toxicology.

Questions Readers Ask

Is tirzepatide just another GLP-1 agonist? Not exactly. It activates GLP-1R, but its sequence is based on GIP and its receptor occupancy tilts toward GIPR (FDA Mounjaro label 2022; Willard 2020).

Are Mounjaro and Zepbound different molecules? No. The FDA describes tirzepatide as the active ingredient of Zepbound and notes that it was already approved under the trade name Mounjaro (FDA Zepbound announcement 2023).

Does the FDA approval cover research-grade "tirzepatide"? No. An approval applies to the sponsor's specific finished drug product under its new drug application (FDA Mounjaro approval letter 2022). Material sold for laboratory research is not that product and has not gone through that review.

What did the end of the shortage change? Certain compounding of tirzepatide injection depended on the product being on the FDA shortage list. Once the shortage was declared resolved, the agency's transition periods for that compounding ran until February 18 and March 19, 2025 (FDA compounding statement 2024).

Handling in the Lab

Research-grade tirzepatide is generally provided as a lyophilized powder. Usual peptide practice applies: keep it frozen (commonly -20 degrees C), dry and shielded from light, make up solutions only when an experiment calls for them, and avoid repeated freeze-thaw cycles. Check identity and purity against the batch Certificate of Analysis.

For research and educational use only. This article is not medical advice and does not describe dosing or human use.